{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T12:11:06Z","timestamp":1789215066771,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2014,9,5]],"date-time":"2014-09-05T00:00:00Z","timestamp":1409875200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s13277-014-2553-1","type":"journal-article","created":{"date-parts":[[2014,9,5]],"date-time":"2014-09-05T01:37:44Z","timestamp":1409881064000},"page":"12389-12395","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer"],"prefix":"10.1007","volume":"35","author":[{"given":"Tuulia","family":"Vallius","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Hynninen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Auranen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olli","family":"Carp\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaakko","family":"Matom\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinikka","family":"Oksa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Virtanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seija","family":"Gr\u00e9nman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,5]]},"reference":[{"issue":"10","key":"2553_CR1","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote I, Trop\u00e9 CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943\u201353.","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"2553_CR2","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/S0959-8049(11)70152-6","volume":"47","author":"I Vergote","year":"2011","unstructured":"Vergote I, Amant F, Kristensen G, Ehlen T, Reed NS, Casado A. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer. Eur J Cancer. 2011;47 Suppl 3:S88\u201392.","journal-title":"Eur J Cancer"},{"issue":"8","key":"2553_CR3","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1245\/s10434-009-0558-6","volume":"16","author":"S Kang","year":"2009","unstructured":"Kang S, Nam BH. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies. Ann Surg Oncol. 2009;16(8):2315\u201320.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"2553_CR4","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.20.5.1248","volume":"20","author":"RE Bristow","year":"2002","unstructured":"Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248\u201359.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2553_CR5","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"A Bois du","year":"2009","unstructured":"du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115(6):1234\u201344.","journal-title":"Cancer"},{"issue":"2","key":"2553_CR6","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"2","key":"2553_CR7","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","volume":"21","author":"GJ Rustin","year":"2011","unstructured":"Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, et al. Definitions for response and progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21(2):419\u201323.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"2553_CR8","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ygyno.2012.02.006","volume":"125","author":"N Rodriguez","year":"2012","unstructured":"Rodriguez N, Rauh-Hain JA, Shoni M, Berkowitz RS, Muto MG, Feltmate C, et al. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 2012;125(2):362\u20136.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2553_CR9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3802\/jgo.2013.24.2.141","volume":"24","author":"N Furukawa","year":"2013","unstructured":"Furukawa N, Sasaki Y, Shigemitsu A, Akasaka J, Kanayama S, Kawaguchi R, et al. CA-125 cut-off value as a predictor for complete interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer. J Gynecol Oncol. 2013;24(2):141\u20135.","journal-title":"J Gynecol Oncol"},{"issue":"1","key":"2553_CR10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00404-010-1655-2","volume":"284","author":"NS Vasudev","year":"2011","unstructured":"Vasudev NS, Trigonis I, Cairns DA, Hall GD, Jackson DP, Broadhead T, et al. The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma. Arch Gynecol Obstet. 2011;284(1):221\u20137.","journal-title":"Arch Gynecol Obstet"},{"issue":"8","key":"2553_CR11","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1093\/annonc\/mdl120","volume":"17","author":"JM Riedinger","year":"2006","unstructured":"Riedinger JM, Wafflart J, Ricolleau G, Eche N, Larbre H, Basuyau JP, et al. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. Ann Oncol. 2006;17(8):1234\u20138.","journal-title":"Ann Oncol"},{"issue":"2","key":"2553_CR12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2010.07.025","volume":"119","author":"AM Altena van","year":"2010","unstructured":"van Altena AM, Kolwijck E, Spanjer MJ, Hendriks JC, Massuger LF, de Hullu JA. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population based study. Gynecol Oncol. 2010;119(2):265\u20139.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2553_CR13","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","volume":"108","author":"RG Moore","year":"2008","unstructured":"Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108(2):402\u20138.","journal-title":"Gynecol Oncol"},{"issue":"8","key":"2553_CR14","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/sj.bjc.6605011","volume":"100","author":"K Huhtinen","year":"2009","unstructured":"Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. 2009;100(8):1315\u20139.","journal-title":"Br J Cancer"},{"issue":"10\u201311","key":"2553_CR15","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.clinbiochem.2011.04.011","volume":"44","author":"Y Park","year":"2011","unstructured":"Park Y, Lee JH, Hong DJ, Lee EY, Kim HS. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clin Biochem. 2011;44(10\u201311):884\u20138.","journal-title":"Clin Biochem"},{"key":"2553_CR16","doi-asserted-by":"crossref","unstructured":"Angioli R, Capriglione S, Aloisi A, Guzzo F, Luvero D, Miranda A, et al. Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer? Tumour Biol. 2014 Apr 21.","DOI":"10.1007\/s13277-014-1836-x"},{"issue":"2","key":"2553_CR17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s13277-009-0015-y","volume":"31","author":"E Anastasi","year":"2010","unstructured":"Anastasi E, Marchei GG, Viggiani V, Gennarini G, Frati L, Reale MG. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol. 2010;31(2):113\u20139.","journal-title":"Tumour Biol"},{"issue":"3","key":"2553_CR18","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ygyno.2012.11.040","volume":"128","author":"R Angioli","year":"2013","unstructured":"Angioli R, Plotti F, Capriglione S, Aloisi A, Montera R, Luvero D, et al. Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? Gynecol Oncol. 2013;128(3):579\u201383.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2553_CR19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ygyno.2012.11.023","volume":"128","author":"EI Braicu","year":"2013","unstructured":"Braicu EI, Fotopoulou C, Van Gorp T, Richter R, Chekerov R, Hall C, et al. Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study. Gynecol Oncol. 2013;128(2):245\u201351.","journal-title":"Gynecol Oncol"},{"key":"2553_CR20","doi-asserted-by":"crossref","first-page":"642e1","DOI":"10.1016\/j.ajog.2008.06.052","volume":"199","author":"A Fagotti","year":"2008","unstructured":"Fagotti A, Ferrandina G, Fanfani F, Garganese G, Vizzielli G, Carone V, et al. Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. Am J Obstet Gynecol. 2008;199:642e1\u20136.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"2553_CR21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3802\/jgo.2011.22.3.183","volume":"22","author":"J Menczer","year":"2011","unstructured":"Menczer J, Usviatzov I, Ben-Shem E, Golan A, Levy T. Neoadjuvant chemotherapy in ovarian, primary peritoneal and tubal carcinoma: can imaging results prior to interval debulking predict survival? J Gynecol Oncol. 2011;22(3):183\u20137.","journal-title":"J Gynecol Oncol"},{"key":"2553_CR22","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2012. ISBN 3-900051-07-0, URL http:\/\/www.R-project.org\/ ."},{"issue":"9","key":"2553_CR23","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1097\/IGC.0b013e3182225509","volume":"21","author":"J Hynninen","year":"2011","unstructured":"Hynninen J, Auranen A, Dean K, Lavonius M, Carpen O, Perheentupa A, et al. Serum HE4 profile during primary chemotherapy of epithelial ovarian cancer. Int J Gynecol Cancer. 2011;21(9):1573\u20138.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"2553_CR24","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/jso.22053","volume":"105","author":"Y Yildirim","year":"2012","unstructured":"Yildirim Y, Ertas IE, Dogan A, Gultekin OE, Gultekin E. The predictors of response to neoadjuvant chemotherapy in advanced epithelial ovarian cancer. J Surg Oncol. 2012;105(2):200\u20135.","journal-title":"J Surg Oncol"},{"issue":"4","key":"2553_CR25","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/jso.23087","volume":"106","author":"F Bellati","year":"2012","unstructured":"Bellati F, Gasparri ML, Caccetta J, Palaia I, Benedetti Panici P. Response criteria can be misleading when drawing conclusion regarding neoadjuvant chemotherapy in advanced ovarian cancer. J Surg Oncol. 2012;106(4):529. author reply 527-8.","journal-title":"J Surg Oncol"},{"issue":"1","key":"2553_CR26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ygyno.2004.09.020","volume":"96","author":"S Tate","year":"2005","unstructured":"Tate S, Hirai Y, Takeshima N, Hasumi K. CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma. J Gynecol Oncol. 2005;96(1):143\u20139.","journal-title":"J Gynecol Oncol"},{"issue":"3","key":"2553_CR27","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.ygyno.2007.02.022","volume":"105","author":"T Le","year":"2007","unstructured":"Le T, Hopkins L, Faught W, Fung-Kee-Fung M. The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking. Gynecol Oncol. 2007;105(3):712\u20135.","journal-title":"Gynecol Oncol"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-014-2553-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-014-2553-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-014-2553-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:29:54Z","timestamp":1559489394000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-014-2553-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,5]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["2553"],"URL":"https:\/\/doi.org\/10.1007\/s13277-014-2553-1","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,5]]}}}